Cronos Group (Cronos Group) ROCE %

: -6.55% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cronos Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -6.55%.

Cronos Group ROCE % Historical Data

The historical data trend for Cronos Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

122.36

-4.20

-10.81

-8.39

-7.12

Cronos Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-9.17	-7.73	-7.26	-7.20	-6.55

Cronos Group ROCE % Calculation

Cronos Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-79.91	/	( ( (1213.009 - 68.116)	+	(1140.085 - 41.399) )	/ 2 )
	=	-79.91	/	( (1144.893	+	1098.686)	/ 2 )
	=	-79.91	/	1121.7895
	=	-7.12 %

Cronos Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-72.676	/	( ( (1150.112 - 30.584)	+	(1140.085 - 41.399) )	/ 2 )
	=	-72.676	/	( ( 1119.528	+	1098.686 )	/ 2 )
	=	-72.676	/	1109.107
	=	-6.55 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cronos Group (NAS:CRON) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cronos Group ROCE % Related Terms

Thank you for viewing the detailed overview of Cronos Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cronos Group (Cronos Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

7CI:Germany CRON:Canada

Address

111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1

Website

https://www.thecronosgroup.com

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.

Executives

Kamran Khan	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii	officer: VP, Controller	C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd.	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc.	10 percent owner	6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm	officer: Chief Financial Officer	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik	officer: General Manager (Israel)	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore	officer: Chief Financial Officer	C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022